InVivo Therapeutics (NASDAQ:NVIV) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of InVivo Therapeutics (NASDAQ:NVIV – Get Rating) in a research report sent to investors on Monday. The firm issued a sell rating on the biotechnology company’s stock. InVivo Therapeutics Trading Down 3.5 % NVIV opened at $1.39 on Monday. InVivo Therapeutics has a 1-year low of $0.81 and a 1-year […]

Related Keywords

,Vanguard Group Inc ,Citadel Advisors ,Renaissance Technologies ,Invivo Therapeutics Holdings Corp ,Invivo Therapeutics ,Get Rating ,Vivo Therapeutics Trading Down ,Sigma Advisers ,Sigma Investments ,Therapeutics Holdings ,Neuro Spinal Scaffold ,Invivo Therapeutics Daily ,Nasdaq Nviv ,Enviv ,Medical ,Initiated Coverage ,Stocknews Com ,